Teva and Cobalt challenge key US patents for Sepracor's Lunesta
This article was originally published in Scrip
Executive Summary
Sepracor has received notice that Teva Pharmaceutical Industries and Cobalt Laboratories have filed ANDAs for generic versions of the sleep agent Lunesta (eszopiclone) tablets, which gained US regulatory clearance in December 2004.